Abstract
Oligonucleotide analogues have recently found wide application in biochemistry and molecular biology as valuable tools for studying interactions of DNA/RNA with other biomolecules [1–3] and as potential candidates for therapeutics in the antisense/antigene or ribozyme strategy [4–6]. Among oligonucleotide congeners most widely used for such a studies are those modified within the internucleotide phosphate group including phosphorothioates, phosphorodithioates, methanephosphonates, phosphoramidates, phosphotriesters etc. The phosphorothioate modification, in which one of the nonbridging oxygen atoms of internucleotide phosphate is substituted by sulphur [7], is most frequently employed in physicochemical and enzymatic studies [8,9]. Phosphorothioate oligodeoxyribonucleotides are also most promising candidates for antisense drugs against several viral and cancer diseases as indicated by their use in numerous clinical trials [10–11], and by recent FDA approval of phosphorothioate 22-mer (Fomivirsen) for treatment of CMV retinitis in AIDS patients (Aug.26, 1998).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Koziołkiewicz, M., Uznański, B., Stec, W.J. and Zon, G. (1986) P-Chiral ai talogues of oligodeoxyribonucleotides: synthesis, stereochemistry and enzyme studies, Chemica Scripta 26, 251–260.
Koziołkiewicz, M. and Stec, W.J. (1992) The application ofbackbonc:-modified oligonucleotides in the studies on Eco RI endonuclease mechanism of action, Biochemisny 31, 9460–9466.
Beaucage, S.L. and Iyer, R.P. (1993) The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications, Tetrahedron 49, 6123–6194.
Zon, G. (1988) Oligonucleotide analogs as potential chemotherapeutic agents, Pharm.Res. 5, 539–549.
Stull, R.A. and Szoka, F.C. (1995) Antigene, ribozyme and aptamer r ucleic acid drugs: progress and prospects, Pharm.Res. 12, 465–483.
Agrawal, S. (ed.) (1996) Antisense Theraputics, Humana Press Inc., Totowa, NJ.
Eckstein, F. (1985) Nucleoside phosphorothioates, Annu.Rev.Biochent. 54, 367–402.
Cohen, J.S. (1993) Phosphorothioate oligonucleotides, in: S.T. Crookt and B. Lebleu (eds.), Antisense Research and Applications, CRC Press, Boca Raton, FL, pp. 205–221.
Brautigam, C.A. and Steitz, T.A. (1998) Structural principles of the inhibition of the 3’-5’ exonuclease activity of Escherichia con DNA polymerase I by phosp iorothioates, J.Mo1.Biol. 227. 363–377.
Glaser, V. (1996) Oligonucleotide therapies move toward efficiacy t ials to treat HIV, CMV, cancer, Genetic Eng.News, Feb.1, pp. 1, 16, 17, 21.
Wickstrom, E. (ed.) (1998) Clinical Trials of Genetic Therapy with.lntisense DNA and DNA Vectors, Marcel Dekker, Inc., New York, NY.
Stec, W.J., Zon, G., Egan, W. and Stec, B. (1984) Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides, J.Am.Chem.Soc. 106, 6077–6079.
Zon, G. and Stec, W.J. (1991) Phosphorothioate oligonucleotides, in: F. Eckstein (ed.), Oligonucleotides and Analogues. A Practical Approach, IRL Press, Oxford, pp. 87–108.
Guga, P., Koziołkiewicz, M., Okruszek, A. and Stec, W.J. (1998) Oli go(nucleoside phosphore thioate)s, in: C..A. Stein and A.M. Krieg (eds.), Applied Antisense Oligonucleotide Technology, Wiley-Liss, Inc., New York, NY, pp. 23–50.
Froehler, B.C. (1986) Deoxynucleoside H-phosphonate diester intern-ediates in the synthesis of intemucleotide phosphate analogs, Tetrahedron Lett. 27, 5575–5578.
Barber, I., Imbach, J.-L. and Rayner, B. (1995) Solution phase synth(sis of phosphorothioate oligonucleotides by the phosphotriester method, Antisense Res.& Dev 5, 39–47.
Agrawal, S. and Tang, J.-Y. (1990) Efficient synthesis of oligoribonu;Ieotide and its phosphorothioate analogue using H-phosphonate approach, Tetrahearon Lett. 31, 7541–7544.
Aimer, A., Stawifiski, J. and Strömberg, R. (1996) Solid support syntlesis of All-Rp-oligo(ribonucleoside phosphorothioate)s, Nucleic Acids Res. 24, 3811–3820.
Wilk, A. and Stec, W.J. (1995) Analysis of oligo(deoxyribonucleosid: phosphorothioate)s and their diastereomeric composition, Nucleic Acids Res. 23, 530–534.
Lesnikowski, Z.J. and Jaworska, M.M. (1989) Studies on stereospeci;ic formation of P-chiral intemucleotide linkage. Synthesis of (RpRp)- and (SpSp)-thymidylyl (3’,5’)thymidyly1(3’,5’)thymidine di(O,O-phosphorothioate) using o-nitrobenzyl group as a new S-protection, Tetrahedron Lett. 30, 3821–3824.
Lesnikowski, Z.J. (1992) he first stereocontrolled synthesis of thiool igoribonucleotide: (RPRP)- and (SPSP)-UPSUPSU, Nucleosides & Nucleotides 11, 1621–1638.
Hacia, J.G., Wold, B.J. and Dervan, P. (1994) Phosphorothioate oligonucleotide-directed triple helix formation, Biochemistry 33, 5367–5369.
Tang, J., Roskey, A., Li, Y. and Agrawal, S. (1995) Enzymatic synthesis of stereoregular All-[Rp] oligonucleotide phosphorothioate and its properties, Nucleosides & Ntcleotides 14, 985–990.
Ueda, T., Tohda, H., Chikazumi, N., Eckstein, F. and Watanabe, K. (1991) Phosphorothioatecontaining RNAs show mRNA activity in the prokaryotic translation; system in vivo, Nucleic Acids Res. 19, 547–552.
Okruszek, A., Guga, P. and Stec, W.J. (1987) Novel approach to the synthesis of isotopomeric monoalkyl [16O,17 O,18O]phosphates. The stereospecific one-pot corn orsion of [RP-thymidine 3’-(4-nitrophenyl)phosphorothioate into [Rd-thymidine 3’-[16O,17O,18O]phosphate, J.Chem.Soc., Chem.Commun., 594–595.
Okruszek, A.,Guga, P. and Stec, W.J. (1991) Stereochemistry of the reaction of ribonucleoside cyclic phosphorothioates with oxiranes, Heteroatom Chem. 2, 561–568.
Stec, W.J., Grajkowski, A., Koziotkiewicz, M. and Uznaríski, B. (1991) Novel route to oligo(deoxy ribonucleoside phosphorothioate)s. Stereocontrolled synthesis of P-chiral oligo(deoxyribonucleoside phosphorothioate)s, Nucleic Acids Res. 21, 5883–5888.
Stec, W.J. and Wilk, A. (1994) Stereocontrolled synthesis of oligo(nu Aeoside phosphorothioate)s, Angew.Chem.Int.Ed.Engl. 33, 709–722.
Brown, T., Pritchard, C.E., Turner, G. and Sailsbury, S.A. (1989) A hew base-stable linker for solid-phase oligonucleotide synthesis, J.Chem.Soc., Chem.Commun., 891–893.
Stec, W.J., Grajkowski, A., Kobylaríska, A., Karwowski, B., Koziolkewicz, M., Misiura, K., Okruszek, A., Wilk, A., Guga, P. and Boczkowska, M. (1995) Diastereomers of nucleoside 3’-O-(2thio-1,3,2-oxathia(selena)phospholane)s: building blocks for stereocontrolled synthesis of oligo (nucleoside phosphorothioate)s, J.Am. Chem. Soc. 117, 12019–12029.
Stec, W.J., Karwowski, B., Guga, P., Misiura, K., Wieczorek, M.W. and Blaszczyk, J. (1996) Stereochemistry of DBU-assisted reaction of nucleoside 3’-O-(2-thiono-1,3,2-oxathiaphospholanes) with 5’-hydroxynucleosides, Phosphorus,Sulfur & Silicon. 109/110, 257–260.
Stec, W.J., Karwowski, B., Boczkowska, M., Guga, P., Koziołkiewicz:, M., Sochacki, M., Wieczorek, M.W. and Blaszczyk, J. (1998) Deoxyribonucleoside 3’-O-(2-thio-and 2-oxo-“spiro”-4,4-pentamethylene1,3,2-oxathiaphospholane)s: monomers for stereocontrolled synthesis)of oligo(deoxyribonucleoside phosphorothioate)s and chimeric PS/PO oligonucleotides, J.Am.Chen.Soc. 120, 7156–7167.
Karwowski, B., Guga, P., Kobylaríska, A. and Stec, W.J. (1998) Nue eoside 3’-O-(2-oxo-“spiro”-4,4-pentamethylene-1,3,2-oxathiaphospholane)s: monomers for stereocon rolled synthesis of oligo (nucleoside phosphorothioate/phosphate)s, Nucleosides & Nucleotides 17, 1747–1759.
Sierzchata, A., Okruszek, A. and Stec, W.J. (1996) Oxathiaphosphoh ne method of stereocontrolled synthesis of diribonucleoside 3’,5’-phosphorothioates, J.Org.Chem. 61, 6713–6716.
Charubala, R. and Pfleiderer, W. (1992) Syntheses and characterizati m of phosphorothioate analogues of (2’-5’)adenylate dimer and trimer and their 5’-O-monophosphates, Helv.Chim.Acta 75, 471–479.
Sobol, R.W., Henderson, E.E., Kong, N., Shao, J., Hitzges, P., Mordechai, E., Reichenbach, N.L., Charubala, R., Schirmeister, H., Pfleiderer, W. and Suhadolnik, R.J. (1995) Inhibition of HIV-1 replication and activation of RNase L by phosphorothioate/phosphodiester 2’,5’-oligoadenylate derivatives, J.BIol.Chem. 270, 5963–5978.
Yang, X.-B., Sierzchala, A., Misiura, K., Niewiarowski, W., Sochacki, M., Stec, W.J. and Wieczorek, M.W. (1998) The first stereocontrolled solid-phase synthesis of di-, tri-, and tetra[adenosine (2’,5’) phosphorothioate]s, J.Org.Chem. 63, 7097–7100.
Torrence, P.F., Xiao, W., Li, G., Cramer, H., Player, M.R. and Silverman, R.H. (1997) Recruiting the 2–5A system for antisense therapeutics, Antisense & Nucl.Acid.Drug Dev. 7, 203–206.
Zon, G., Sumers, M.F., Gallo, K.A., Shao, K.-L, Koziołkiewicz, M., Jznaliski, B. and Stec, W.J. (1987) Stereochemistry of phosphorothioate phosphotriesters, in: Biosphates and Their Analogues - Synthesis, Structure, Metabolism and Activity, K.S. Bruzik and W.J. Stec (eds.), Elsevier, Amsterdam, pp. 165–178.
Jaroszewski, J.W., Sui, J., Majzel, J. and Cohen, J.S. (1992) Towards rational design of antisense DNA: molecular modelling of phosphorothioate DNA analogues, Anti-Cane per Drug Design. 7, 253–262.
Koziołkiewicz, M., Krakowiak, A, Kwinkowki, M., Boczkowska, M and Stec, W.J. (1995) Stereodifferentiation - the effect of P-chirality of oligo(nucleoside pho;phorothioate)s on the activity of bacterial RNase H, Nucleic Acids Res. 23, 5000–5005.
Stec, W.J., Ciemiewski, C.S., Okruszek, A, Kobylańska, A., Pawlowska, Z., Koziołkiewicz, M., Pluskota, E., Maciaszek, A., Rębowska, B. and Stasiak, M. (1997) Stereodependent inhibition of Plasminogen Activator Inhibitor Type 1 by phosphorothioate oligonucleotides: proof of sequence specificity in cell culture and in vivo rat experiments, Antisense & NuclAcids Drug Dev. 7, 567–573.
Koziołkiewicz, M., Wójcik, M., Kobylańska, A, Karwowski, B., Rgbowska, B., Guga, P. and Stec, W.J. (1997) Stability of stereoregular oligo(nucleoside phosphorothio tte)s in human plasma: diastereoselectivity of plasma 3’-exonuclease, Antisense & NuclAcid. Drug Dev. 7, 43–48.
Koziołkiewicz, M., Gendaszewska, E. and Maszewska, M. (1997) Stability of stereoregular oligo(nucleoside phosphorothioate)s in human cells. Diastereoselectivity of cellular 3’exonuclease, Nucleosides & Nucleotides 16, 1677–1682.
Krakowiak, A and Koziołkiewicz, M. (1998) Influence of P-chirality of phosphorothioate oligonucleotides on the activity of AMV-reverse transcriptase, Nucleosides & Nucleotides 17, 1823–1834.
Koziołkiewicz, M., Maciaszek, A, Stec, W.J., Semizarov, D., Victorova, L. and Krayevsky, A. (1998) Effect of P-chirality of oligo(nucleoside phosphorothioate)s on the act vity of terminal deoxyribonucleotidyl transferase, FEES Letters 434, 77–82.
Benimetskaya, L, Tonkinson, J.L., Koziołkiewicz, M., Karwowski, B., Guga, P., Zeltser, R., Stec, W.J. and Stein, C.A. (1995) Binding of phosphorothioate oligonucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent, Nucleic Acids Res. 23, 4239–4245.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Okruszek, A. (1999). Oxathiaphospholane Method of the Stereocontrolled Synthesis of Phosphorothioate Analogues of Oligonucleotides. In: Barciszewski, J., Clark, B.F.C. (eds) RNA Biochemistry and Biotechnology. NATO Science Series, vol 70. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4485-8_24
Download citation
DOI: https://doi.org/10.1007/978-94-011-4485-8_24
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-5862-6
Online ISBN: 978-94-011-4485-8
eBook Packages: Springer Book Archive